OBJECTIVE: To evaluate the variables affecting orthotopic liver transplantation (OLT) outcome for hepatitis B virus (HBV) in a large patient cohort over a 17-year period. SUMMARY BACKGROUND DATA: Historically, OLT for chronic HBV infection has been associated with aggressive reinfection and poor survival results. More recently, OLT outcome has been improved with the routine use of antiviral therapy with either hepatitis B immune globulin (HBIg) or lamivudine; however, HBV recurrence remains common. The authors studied the factors affecting HBV recurrence and outcome of transplantation, including the effects of combination viral prophylaxis with HBIg and lamivudine. METHODS: A retrospective review of 166 OLT recipients for chronic HBV over a 17-year period at a single center was performed. Median follow-up was 29 months. HBV recurrence was defined by HBsAg seropositivity after OLT. HBIg monotherapy was used in 28 (17%) patients, lamivudine monotherapy in 20 (12%), and HBIg and lamivudine combination in 89 (54%); 29 (17%) did not receive any HBV prophylaxis. Hepatocellular carcinoma (HCC) was present in 43 patients (26%) and urgent United Network for Organ Sharing (UNOS) status was assigned to 27 patients (16%). Univariate and multivariate analyses were performed to identify factors that affected OLT outcome. RESULTS: Overall 1-, 3-, and 5-year patient survival rates were 85.8%, 73.6%, and 71.8%, respectively. As expected, HBV recurrence-free survival rates were significantly lower than overall survival rates (76.4%, 58.7%, and 48.3%). When compared with a nontreated cohort, OLT recipients receiving combination viral prophylaxis with HBIg and lamivudine showed markedly reduced HBV recurrence rates and significantly improved 1- and 3-year recurrence-free survival rates. By univariate estimates, patient survival was reduced in the presence of HCC, in the Asian population, and urgent candidates by UNOS classification. Graft loss rates were significantly increased in urgent OLT candidates, Asians, patients with pretransplant positive DNA, and in the presence of HCC. Factors that were significant by univariate analysis or thought to be clinically relevant were subjected to multivariate analysis. By multivariate estimates, urgent UNOS or presence of HCC adversely affected patient and graft survival rates, whereas combination prophylactic therapy strongly predicted improved patient and graft survival rates as well as recurrence-free survival rates. CONCLUSIONS: Orthotopic liver transplantation for HBV under combination viral prophylaxis results in survival rates equivalent to other indications. Pretransplant viral replication, UNOS status, and the presence of HCC are all sensitive markers for posttransplantation outcome. Viral prophylactic therapy has effectively reduced HBV recurrence and prolonged survival outcomes. The combination of HBIg and lamivudine is the prophylactic regimen of choice.
OBJECTIVE: To evaluate the variables affecting orthotopic liver transplantation (OLT) outcome for hepatitis B virus (HBV) in a large patient cohort over a 17-year period. SUMMARY BACKGROUND DATA: Historically, OLT for chronic HBV infection has been associated with aggressive reinfection and poor survival results. More recently, OLT outcome has been improved with the routine use of antiviral therapy with either hepatitis B immune globulin (HBIg) or lamivudine; however, HBV recurrence remains common. The authors studied the factors affecting HBV recurrence and outcome of transplantation, including the effects of combination viral prophylaxis with HBIg and lamivudine. METHODS: A retrospective review of 166 OLT recipients for chronic HBV over a 17-year period at a single center was performed. Median follow-up was 29 months. HBV recurrence was defined by HBsAg seropositivity after OLT. HBIg monotherapy was used in 28 (17%) patients, lamivudine monotherapy in 20 (12%), and HBIg and lamivudine combination in 89 (54%); 29 (17%) did not receive any HBV prophylaxis. Hepatocellular carcinoma (HCC) was present in 43 patients (26%) and urgent United Network for Organ Sharing (UNOS) status was assigned to 27 patients (16%). Univariate and multivariate analyses were performed to identify factors that affected OLT outcome. RESULTS: Overall 1-, 3-, and 5-year patient survival rates were 85.8%, 73.6%, and 71.8%, respectively. As expected, HBV recurrence-free survival rates were significantly lower than overall survival rates (76.4%, 58.7%, and 48.3%). When compared with a nontreated cohort, OLT recipients receiving combination viral prophylaxis with HBIg and lamivudine showed markedly reduced HBV recurrence rates and significantly improved 1- and 3-year recurrence-free survival rates. By univariate estimates, patient survival was reduced in the presence of HCC, in the Asian population, and urgent candidates by UNOS classification. Graft loss rates were significantly increased in urgent OLT candidates, Asians, patients with pretransplant positive DNA, and in the presence of HCC. Factors that were significant by univariate analysis or thought to be clinically relevant were subjected to multivariate analysis. By multivariate estimates, urgent UNOS or presence of HCC adversely affected patient and graft survival rates, whereas combination prophylactic therapy strongly predicted improved patient and graft survival rates as well as recurrence-free survival rates. CONCLUSIONS: Orthotopic liver transplantation for HBV under combination viral prophylaxis results in survival rates equivalent to other indications. Pretransplant viral replication, UNOS status, and the presence of HCC are all sensitive markers for posttransplantation outcome. Viral prophylactic therapy has effectively reduced HBV recurrence and prolonged survival outcomes. The combination of HBIg and lamivudine is the prophylactic regimen of choice.
Authors: M A Petit; D Buffello-Le Guillou; B Roche; E Dussaix; J C Duclos-Vallée; C Féray; D Samuel Journal: J Med Virol Date: 2001-11 Impact factor: 2.327
Authors: R M Ghobrial; R Steadman; J Gornbein; C Lassman; C D Holt; P Chen; D G Farmer; H Yersiz; N Danino; E Collisson; A Baquarizo; S S Han; S Saab; L I Goldstein; J A Donovan; K Esrason; R W Busuttil Journal: Ann Surg Date: 2001-09 Impact factor: 12.969
Authors: D Mutimer; G Dusheiko; C Barrett; L Grellier; M Ahmed; G Anschuetz; A Burroughs; S Hubscher; A P Dhillon; K Rolles; E Elias Journal: Transplantation Date: 2000-09-15 Impact factor: 4.939
Authors: S H Han; J Ofman; C Holt; K King; G Kunder; P Chen; S Dawson; L Goldstein; H Yersiz; D G Farmer; R M Ghobrial; R W Busuttil; P Martin Journal: Liver Transpl Date: 2000-11 Impact factor: 5.799
Authors: J S Markowitz; P Martin; A J Conrad; J F Markmann; P Seu; H Yersiz; J A Goss; P Schmidt; A Pakrasi; L Artinian; N G Murray; D K Imagawa; C Holt; L I Goldstein; R Stribling; R W Busuttil Journal: Hepatology Date: 1998-08 Impact factor: 17.425
Authors: Ronald W Busuttil; Douglas G Farmer; Hasan Yersiz; Jonathan R Hiatt; Sue V McDiarmid; Leonard I Goldstein; Sammy Saab; Steven Han; Francisco Durazo; Michael Weaver; Carlos Cao; Tony Chen; Gerald S Lipshutz; Curtis Holt; Sherilyn Gordon; Jeffery Gornbein; Farin Amersi; Rafik M Ghobrial Journal: Ann Surg Date: 2005-06 Impact factor: 12.969
Authors: Rohit Loomba; Ayana K Rowley; Robert Wesley; Karen G Smith; T Jake Liang; Frank Pucino; Gyorgy Csako Journal: Clin Gastroenterol Hepatol Date: 2008-05-05 Impact factor: 11.382
Authors: R T Chung; F D Gordon; M P Curry; T D Schiano; S Emre; K Corey; J F Markmann; M Hertl; J J Pomposelli; E A Pomfret; S Florman; M Schilsky; T J Broering; R W Finberg; G Szabo; P D Zamore; U Khettry; G J Babcock; D M Ambrosino; B Leav; M Leney; H L Smith; D C Molrine Journal: Am J Transplant Date: 2013-01-28 Impact factor: 8.086